Axsome Therapeutics (AXSM) Profit After Tax (2015 - 2026)

Axsome Therapeutics (AXSM) has 12 years of Profit After Tax data on file, last reported at -$64.5 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax fell 8.63% year-over-year to -$64.5 million; the trailing twelve-month figure through Mar 2026 stood at -$188.3 million (up 32.33% YoY), and the FY2025 full-year result was -$183.2 million, up 36.22% from the prior year.
• Profit After Tax declined to -$64.5 million in Q1 2026, from -$28.6 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $125.7 million in Q4 2022 to a low of -$98.7 million in Q4 2023.
• A 5-year average of -$45.6 million and a median of -$59.4 million in 2025 frame the typical range for Profit After Tax.
• Across the five-year window, Profit After Tax jumped 469.91% in 2022 and tumbled 509.35% in 2024, its largest moves.
• Tracing AXSM's Profit After Tax over 5 years: stood at $125.7 million in 2022, then slumped by 178.49% to -$98.7 million in 2023, then increased by 24.06% to -$74.9 million in 2024, then jumped by 61.88% to -$28.6 million in 2025, then sank by 126.0% to -$64.5 million in 2026.
• Business Quant data shows AXSM's Profit After Tax at -$64.5 million in Q1 2026, -$28.6 million in Q4 2025, and -$47.2 million in Q3 2025.